Comparative Pharmacology
Head-to-head clinical analysis: HOMAPIN 10 versus HOMAPIN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HOMAPIN 10 versus HOMAPIN 5.
HOMAPIN-10 vs HOMAPIN-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Homapin-10 is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Homapin-5 is a combination product containing homatropine methylbromide, an antimuscarinic agent that inhibits the action of acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretion.
10 mg orally every 8 hours as needed for extrapyramidal symptoms; maximum 30 mg per day.
Adults: 5 mg orally every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases), necessitating dose adjustment.
Terminal half-life 3-5 hours; clinically effective half-life 4 hours for motor response in Parkinson's disease.
HOMAPIN-10 is primarily excreted renally as unchanged drug (70-80%), with biliary/fecal elimination accounting for 15-20% and minor metabolism 5-10%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% as metabolites in urine.
Category C
Category C
Anticholinergic (Mydriatic)
Anticholinergic (Mydriatic)